Analysis of the main mechanism of action and indications and therapeutic effects of Alpelisib

Alpelisib (Alpelisib) is an oral and selective PI3Kα (phosphatidylinositol 3-kinase alpha isoform) inhibitor. PI3KThe signaling pathway plays a key role in the growth, proliferation and survival of various tumor cells. In particular, mutations in the PIK3CA gene lead to abnormal activation of this pathway, which is an important cause of drug resistance and malignant progression of various cancers. By inhibiting the activity of PI3Kα isoform, Apelvis effectively blocks the proliferation signals of tumor cells and induces apoptosis, thereby inhibiting tumor growth.

Apelix is mainly approved for PIK3CA gene mutation-positive hormone receptor-positive (HR+), HER2Patients with n>HER2negative advanced or metastatic breast cancer are often given in combination with endocrine therapy (such as fulvestrantFulvestrant ). This indication is targeted at patients who are resistant or progressing to endocrine therapy and provides a new treatment option for these patients.

Clinical studies (such as theSOLAR-1 trial) have shown that apelvis combined with endocrine therapy significantly prolongs PIK3CAThe progression-free survival (PFS) of patients with n> mutations, compared with endocrine therapy alone, the median PFS of the treatment group was significantly improved. At the same time, this combination treatment also improved the patient's objective response rate (ORR) and demonstrated good clinical anti-tumor activity.

Common side effects of Apelix include hyperglycemia, rash, diarrhea, fatigue, etc. Some patients may develop severe diabetes or skin toxicity, so blood sugar and skin conditions need to be closely monitored. Patient education should be strengthened during medication, adverse reactions should be discovered and dealt with in a timely manner, and dosage should be adjusted or treatment suspended if necessary. Overall, Apelvis provides a powerful new targeted treatment option for PIK3CA mutation-positive breast cancer patients and improves the prognosis.

Reference materials:https://www.drugs.com/